News Search Results
Dec 07, 2023, 21:15 ET Retinopathy of Prematurity Epidemiology Forecasts, 2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
Bethesda, USA, Stanley Manne Children's Research Institute, United Kingdom, MD, Ophthalmology - Oakland, USA, North Shore University Health System, MD, Lurie Children's Hospital
More news about: Research and Markets
Dec 07, 2023, 18:06 ET Mallinckrodt Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® (nitric oxide) Mini-Cylinder
segments areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products.
More news about: Mallinckrodt plc
Dec 07, 2023, 02:57 ET Sectra leads the market in PACS considerations and selections
systems worldwide. Sectra offers a complete enterprise solution comprised of imaging modules (radiology, cardiology, pathology, orthopedics, and ophthalmology), and a robust VNA. Over the last ten consecutive years, Sectra has been awarded Best in KLAS for highest customer satisfaction. For more information,
More news about: Sectra
Dec 06, 2023, 20:00 ET Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announces the licensing deal expansion with Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing
More news about: Innovent Biologics
Dec 06, 2023, 20:00 ET Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases. Building on the core value proposition of Synaffix ADC technology – to enable best-in-class efficacy and tolerability
More news about: Synaffix
Dec 06, 2023, 07:00 ET InMode Revises Full-Year 2023 Guidance
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode LTD
Dec 05, 2023, 19:16 ET Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced the interim analysis results of ORIENT-16, the Phase 3 study evaluating sintilimab in combination with chemotherapy
More news about: Innovent Biologics
Dec 05, 2023, 10:01 ET RNA- Based Therapeutic Market worth $29.41 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
RNA- Based Therapeutic Market- by Drug Class (RNA Aptamer, siRNA, Antisense RNA, mRNA), By Therapeutic Area (Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
More news about: InsightAce Analytic Pvt. Ltd
Dec 05, 2023, 06:00 ET Leapfrog Group Announces 2023 Top Hospitals and Top ASCs
75 Top Teaching Hospitals. A total of 27 ASCs earned the Top ASC Award. Nine specialties were represented: gastroenterology, general surgery, ophthalmology, otolaryngology, orthopedic surgery, urology, neurological surgery, obstetrics and gynecology, and plastic and reconstructive surgery. "This
More news about: The Leapfrog Group
Dec 04, 2023, 11:15 ET Global Biosimilars Market Report 2023-2028: Reimbursement and Payer Landscape Influence Biosimilar Adoption
Reset in Response to IRADual Pricing Strategy in the USUS OncologyUS Oncology Supportive CareUS Immunology and OphthalmologyEurope Competitive Benchmarking - Key CountriesMarket Snapshot - Europe Biosimilars MarketBiosimilars Approved in
More news about: Research and Markets
Dec 01, 2023, 21:35 ET Artificial Eye Market size to grow by USD 56.43 million from 2023-2028, North America to account for 57% of market growth - Technavio
India and China deliver several opportunities for the global artificial eye market. Thus, owing to the presence of a large patient pool with ophthalmology conditions that can lead to partial and complete blindness, a peak in awareness about ocular prosthesis, improvements in healthcare infrastructure,
More news about: Technavio
Dec 01, 2023, 07:00 ET Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress
C.E.T.Location: Cavalieri Waldorf Astoria Hotel & Congress CenterPresenter: Francesco Bandello, MD, FEBO, Professor and Chairman Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele, Milan In his presentation, Professor Bandello will discuss
More news about: Nanoscope Therapeutics
Dec 01, 2023, 02:35 ET Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for CVDs and orphan diseases is the major market trend- Technavio
- Segmentation AssessmentSegment OverviewTechnavio has segmented the market based on therapy areas (oncology, CNS, ophthalmology, rare diseases, and others), and delivery mode (in vivo and ex vivo). The market growth in the oncology segment will be
More news about: Technavio
Nov 30, 2023, 23:00 ET Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023
biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces the publication of updated clinical data of IBI351 (KRAS G12C inhibitor) monotherapy in non-small cell lung
More news about: Innovent Biologics
Nov 30, 2023, 20:45 ET Global Adaptive Optics Business Analysis Report 2023: Market to Reach $14.8 Billion by 2030 from $1.3 Billion in 2022 - Surge in Demand for High-Resolution Microscopy in Biomedical Research
Operations Bodes Well for AO MarketAdaptive Optics Gains Ground in Brain ImagingAdaptive Optics (AO) Expands Applications in OphthalmologyAdaptive Optics Vs Optical Coherence TomographyGlobal Burden of Eye Diseases:Leading Causes of Blindness Worldwide (in
More news about: Research and Markets
Nov 30, 2023, 19:45 ET Global Computational Fluid Dynamics (CFD) Market Report, 2022 and 2023-2030 - Myriad Benefits of CFD Provide Growth Opportunities, Fueling a Multi-Billion Industry
Technologies Market Size (in US$ Billion) for Years 2021, 2023, 2025 and 2027Promising & Emerging Clinical Applications of CFD Analysis in OphthalmologyCFD Modeling & Simulation for Hydrofracking Reactors and Crude Oil PipelinesCFD Solutions Find Use in All Aspects of Oil &
More news about: Research and Markets
Nov 30, 2023, 15:50 ET ZEISS INSPECT - Release of the new 3D metrology software for a wide range of challenges
assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture
More news about: Carl Zeiss Industrial Quality Solutions, LLC
Nov 30, 2023, 13:47 ET AMSURG Announces Board of Directors
health systems, the organization delivers high-quality patient care across a diverse spectrum of medical specialties, including gastroenterology, ophthalmology and orthopedics. With a focus on strategic growth and innovation, AMSURG is committed to transforming the future of ambulatory surgery center care
More news about: AMSURG
Nov 30, 2023, 11:00 ET Medical Laser Market to Reach $17073.8 Million, by 2032 at 11.3% CAGR: Allied Market Research
Laser Market by Product Type (Solid State Laser Systems, Gas Laser Systems, Dye Laser Systems, and Diode Laser Systems), Application (Ophthalmology Lasers, Surgical Lasers, Aesthetic and Dermatology Lasers, And Others), and End User (Hospital, Dermatology and Cosmetic Clinics, Ophthalmic Clinics,
More news about: Allied Market Research
Nov 30, 2023, 07:00 ET Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII
Ophthalmology Innovation Summit (OIS) taking place from December 1-2 in San Diego, California.
More news about: Nanoscope Therapeutics
Nov 30, 2023, 07:00 ET Innovent's MSCI ESG Rating Upgraded to A
biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the Company has been upgraded to 'A' according to Morgan Stanley Capital International's (MSCI) latest
More news about: Innovent Biologics
Nov 30, 2023, 06:07 ET Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe
Trastuzumab, Adalimumab, and Etanercept. At a global level, Biocon Biologics has a robust pipeline of 20 assets for diabetology, oncology, immunology, ophthalmology, and bone health. Serving over 5.7M patients annually, the Company is committed to providing access to high-quality therapies and solutions to patients,
More news about: Biocon Biologics Ltd.
Nov 30, 2023, 05:47 ET Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe
Trastuzumab, Adalimumab, and Etanercept. At a global level, Biocon Biologics has a robust pipeline of 20 assets for diabetology, oncology, immunology, ophthalmology, and bone health. Serving over 5.7M patients annually, the Company is committed to providing access to high-quality therapies and solutions to patients,
More news about: Biocon Biologics Ltd.
Nov 29, 2023, 13:24 ET Unither Pharmaceuticals celebrates 30 years of innovation and expertise
inNanjing, consolidated its global footprint. In 2022, Unither further expanded its activities with the acquisition of a new site specializing in ophthalmology in São Paulo. This international development is designed to support its customers' international industrial strategies by getting closer to their
More news about: Unither Pharmaceuticals
Nov 29, 2023, 13:02 ET Unither Pharmaceuticals celebrates 30 years of innovation and expertise
inNanjing, consolidated its global footprint. In 2022, Unither further expanded its activities with the acquisition of a new site specializing in ophthalmology in São Paulo. This international development is designed to support its customers' international industrial strategies by getting closer to their
More news about: Unither Pharmaceuticals